2025/11/30 by Nita Radhakrishnan, Jagdish Chandra, Mamta Manglani +3 · 1 voice
Medicine · #Hemoglobinopathies and Related Disorders #Iron Metabolism and Disorders #Voice and Speech Disorders
paper · doi:10.1111/vox.70157
openalex publication_date 2025/11/30 · openalex created_date 2025/12/01 · openalex updated_date 2026/07/25
BACKGROUND AND OBJECTIVES: India, home to the largest population of patients with thalassaemia major (TM), has made notable progress in the care through the National Health Mission, National Rare Disease Registry and Thalassaemia Bal Sewa Yojana. This study aimed to assess the infrastructure, support systems and human resources across thalassaemia treatment centres in India to map current service availability and guide policy enhancements for its prevention and comprehensive management. MATERIALS AND METHODS: A nationwide survey was conducted between January 2023 and March 2024 among centres managing TM. The survey was disseminated through professional groups, civil societies and non-governmental organizations. RESULTS: Sixty-eight centres participated (government 26, private 28, charitable 14). About 85% of patients were from low-income families, highlighting the dependence on government support. Transfusion services with leukodepleted red cells were available in 97% of centres, with most maintaining adequate pre-transfusion haemoglobin. Chelation service was accessible in the majority of centres, and 87% provided prenatal diagnostics. Bone marrow transplantation was offered in 60 centres and comprehensive care services in 58 centres. Despite free transfusions and chelation, monthly out-of-pocket costs ranged from Indian rupees (INR) ₹500 to ₹16,000 (US 5.92-189.49). CONCLUSION: Government initiatives have expanded thalassaemia services and reduced financial barriers. Continued efforts to strengthen the national registry and unify policy frameworks will help ensure equitable access across all regions.